Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) Net Income towards Common Stockholders (2016 - 2025)

Vycor Medical has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$62686.0 for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 830.47% to -$62686.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$396796.0 through Dec 2025, up 8.06% year-over-year, with the annual reading at -$396796.0 for FY2025, 8.06% up from the prior year.
  • Net Income towards Common Stockholders was -$62686.0 for Q4 2025 at Vycor Medical, up from -$157249.0 in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $68406.0 in Q2 2023 and troughed at -$405104.0 in Q1 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$156286.0 (2023), against an average of -$135587.3.
  • Year-over-year, Net Income towards Common Stockholders tumbled 956.22% in 2022 and then soared 337.97% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$187062.0 in 2021, then soared by 37.7% to -$116548.0 in 2022, then rose by 20.16% to -$93055.0 in 2023, then skyrocketed by 92.76% to -$6737.0 in 2024, then tumbled by 830.47% to -$62686.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Net Income towards Common Stockholders are -$62686.0 (Q4 2025), -$157249.0 (Q3 2025), and $23887.0 (Q2 2025).